Please assess the completion status of the following clinical trial:

Trial Title: A Pilot Study of BMS-512148 in Subjects With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Males and females, 18 to 75 years old, with type 2 diabetes with inadequate glycemic control~* Subjects receiving insulin and metformin and/or a thiazolidinedione~* Body Mass Index \<=45.0 kg/m2~* Serum creatinine \<1.5 mg/dL for men or \<1.4 mg/dL for women~* No overt proteinuria (in subjects with a microalbumin/creatinine ratio ≥300 mg/g, the 24-hour urinary excretion of total protein must be \<3 g/24 hrs)~Exclusion Criteria:~* History of type 1 diabetes~* AST and/or ALT \>2.5 times the upper limit of normal~* Creatinine kinase ≥3 times the upper limit of normal~* Symptoms of severely uncontrolled diabetes~* History of hypoglycemic unawareness~* Currently unstable or serious cardiovascular, renal, hepatic, hematological, oncological, endocrine, psychiatric, or rheumatic diseases

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Cohort 1 (Type: EXPERIMENTAL): 20 mg
- Cohort 2 - Arm 1 (Type: EXPERIMENTAL): 10 mg
- Cohort 2 - Arm 2 (Type: EXPERIMENTAL): 20 mg
- Cohort 2 - Arm 3 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).